Table 2 Common treatment-emergent adverse events (most to least prevalent)
From: A controlled trial of quetiapine XR coadministration treatment of SSRI-resistant panic disorder
Adverse event | Quetiapine XR n = 13 (N, %) | Placebo n = 13 (N, %) |
|---|---|---|
Somnolencea | 10 (77 %) | 5 (38 %) |
Anxiety | 4 (31 %) | 0 (0 %) |
Constipation | 3 (23 %) | 1 (8 %) |
Dry mouth | 3 (23 %) | 0 (0 %) |
Dizziness | 2 (15 %) | 3 (23 %) |
Restlessness | 2 (15 %) | 4 (31 %) |
Derealizationa | 2 (15 %) | 0 (0 %) |
Insomnia | 1 (8 %) | 3 (23 %) |
Increased appetite | 1 (8 %) | 2 (15 %) |
Leg pain | 1 (8 %) | 1 (8 %) |
Weight loss | 1 (8 %) | 0 (0 %) |
Shakiness | 1 (8 %) | 0 (0 %) |
Muscle aches | 0 (0 %) | 2 (15 %) |
Weight gain | 0 (0 %) | 1 (8 %) |